Comparison of two treatment methods for Alopecia Areata (Patchy hair loss)

INTERVENTION: Intervention1: Majoon‐e‐Chobchini, Microneedling: Microneedling and Majoon‐e‐ chobchini will be given for the duration of 10 weeks. Microneedling include needles, characterized by their micron‐sized sharp tips, can painlessly penetrate the skin and have shown significant potential in disease treatment. Depth of microneedling 0.5‐1.5mm will be used for this study. It creating tiny micro‐injuries. Your skin responds by sending more blood flow to the area and rebuilding its collagen to heal the wounds. This wound‐healing response also happens on your scalp, which can help regrow hair in some cases. Control Intervention1: Majoon‐e‐Chobchini, Zimad‐e‐khardal: Majoon‐e‐Chobchini and Zimad‐e‐ khardal both will be given for the duration of 10 weeks. Majoon‐e‐Chobchini is an Unani polyherbal formulation traditionally used for the management of dermatological disorders, particularly those associated with altered temperament of humours (Sue Mizaj‐e‐khilt) . It possesses immunomodulatory properties, blood‐purifying, anti‐inflammatory which are beneficial in conditions like Alopecia areata Zimad Khardal is a Unani topical formulation containing mustard (Khardal) as the principal ingredient. It is used for its counter‐irritant (Muhammir), rubefacient, and local stimulant properties, which enhance blood circulation. CONDITION: Health Condition 1: L638‐ Other alopecia areata PRIMARY OUTCOME: A)Severity of Alopecia Tool (SALT) score ; B)Trichoscopy ; C)Alopecia Areata symptom impact scale (AASIS) ; D)Photographs of lesionTimepoint: At 15th, 30th, 45th, 60th, 75th day. SECONDARY OUTCOME: Dermatology Life Quality of LifeTimepoint: At 15th, 30th, 45th, 60th, 75th day. INCLUSION CRITERIA: 1‐Clinically diagnosed cases of Alopecia areata. [characterized by patchy, non‐scarring hairloss with smooth scalp surface on inspection,presence of exclamation mark hairs on tricoscopy, History of associated Autoimmune ‐condition(s). 2‐Clinically stable patients. 3‐Patients of either gender. 4‐Patients between 18‐60 Years of age. 5‐Patient not on any concomitant therapy. 6‐Patient who has left the treatment at least 2 months back. 7‐Patient willing to sign the written consent proforma. 8‐Patient who follows the protocol.